ACCME weighs pharma-free labeling

Share this article:
The Accreditation Council for Continuing Medical Education (ACCME) is considering offering an accreditation flagging CME as being free of drug and device industry support—a kind of Good Housekeeping Seal for CME.

The accrediting body issued a call for public comment on the proposal, saying: “The ACCME recognizes that some stakeholders want to differentiate between CME that does include relationships with industry from CME that does not include relationships with industry. To clarify this differentiation, the ACCME will consider creating a new designation and review process for providers that wish to identify their program of CME as one that does not utilize funds from commercial interests that have been donated to support continuing medical education.”

Such programs, ACCME said, would not accept any commercial support for any CME activity or any part of its CME program and would not use funds from advertising or promotion paid for by a commercial interest to underwrite costs of CME.

ACCME is also considering a similar designation for programs that do not use teachers or authors “that have acted for a commercial interest in promotional and marketing activities.”

And ACCME is considering setting up an independent CME funding entity that would collect and disburse unrestricted CME funds from industry sources. The group is accepting public comments on all three proposals through May 21.

Earlier in April, the accrediting body announced that it was no longer considering a ban on commercial support of CME.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.